- Oops!Something went wrong.Please try again later.
The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia.
MB-106 is a CD20-targeted, autologous CAR T cell therapy.
In addition, the Office for Human Research Protections has approved Federalwide Assurance for Mustang's research for the protection of human subjects in research.
Price Action: MBIO shares are up 3.98% at $2.32 during the market session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.